Recent Advances in Protective Vaccines against Hepatitis Viruses: A Narrative Review

Viruses. 2023 Jan 12;15(1):214. doi: 10.3390/v15010214.

Abstract

Vaccination has been confirmed to be the safest and, sometimes, the only tool of defense against threats from infectious diseases. The successful history of vaccination is evident in the control of serious viral infections, such as smallpox and polio. Viruses that infect human livers are known as hepatitis viruses and are classified into five major types from A to E, alphabetically. Although infection with hepatitis A virus (HAV) is known to be self-resolving after rest and symptomatic treatment, there were 7134 deaths from HAV worldwide in 2016. In 2019, hepatitis B virus (HBV) and hepatitis C virus (HCV) resulted in an estimated 820,000 and 290,000 deaths, respectively. Hepatitis delta virus (HDV) is a satellite virus that depends on HBV for producing its infectious particles in order to spread. The combination of HDV and HBV infection is considered the most severe form of chronic viral hepatitis. Hepatitis E virus (HEV) is another orally transmitted virus, common in low- and middle-income countries. In 2015, it caused 44,000 deaths worldwide. Safe and effective vaccines are already available to prevent hepatitis A and B. Here, we review the recent advances in protective vaccines against the five major hepatitis viruses.

Keywords: HAV; HBV; HCV; HDV; HEV; vaccine; viral hepatitis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hepatitis A virus*
  • Hepatitis A*
  • Hepatitis B virus
  • Hepatitis B* / prevention & control
  • Hepatitis C*
  • Hepatitis Delta Virus
  • Hepatitis Viruses
  • Humans
  • Vaccines*

Substances

  • Vaccines

Grants and funding

This article was supported by funds from the Japan agency for medical research and development number 22fk0310503j0101, 22fk0310513j0701, and 22fk0310507j0901 to H.H.A.